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s u m m a r y
Obstructive sleep apnoea-hypopnoea (OSAH) causes excessive daytime sleepiness, impairs quality-of-
life, and increases cardiovascular disease and road trafﬁc accident risks. Continuous positive airway
pressure (CPAP) treatment and mandibular advancement devices (MAD) have been shown to be effective
in individual trials but their effectiveness particularly relative to disease severity is unclear.
A MEDLINE, Embase and Science Citation Index search updating two systematic reviews to August
2013 identiﬁed 77 RCTs in adult OSAH patients comparing: MAD with conservative management (CM);
MAD with CPAP; or CPAP with CM. Overall MAD and CPAP signiﬁcantly improved apnoea-hypopnoea
index (AHI) (MAD 9.3/hr (p < 0.001), CPAP 25.4 (p < 0.001)). In direct comparisons mean AHI and
Epworth sleepiness scale score were lower (7.0/hr (p < 0.001) and 0.67 (p ¼ 0.093) respectively) for CPAP.
There were no CPAP vs. MAD trials in mild OSAH but in comparisons with CM, MAD and CPAP reduced
ESS similarly (MAD 2.01 (p < 0.001); CPAP 1.23 (p ¼ 0.012).
Both MAD and CPAP are clinically effective in the treatment of OSAH. Although CPAP has a greater
treatment effect, MAD is an appropriate treatment for patients who are intolerant of CPAP and may be
comparable to CPAP in mild disease.
Crown Copyright © 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Obstructive sleep apnoea-hypopnoea (OSAH) is characterised by
repeated interruption of breathing during sleep due to episodic
collapse of the pharyngeal airway. These episodes usually cause
oxygen desaturation and are terminated by micro-arousals from
sleep. This sleep disruption commonly causes excessive daytime
sleepiness (EDS) [1].
Published studies suggest that OSAH affects 2%e7% of the adult
population [2]. It becomes more prevalent in middle age and males
have approximately double the risk of developing the condition [3].
The main modiﬁable risk factor for OSAH is obesity, particularly
when adiposity is distributed around the neck and upper body [4].
Others include smoking and alcohol use. Medical conditions such
as hypothyroidism, polycystic ovary syndrome and acromegaly
have also been associated with OSAH [2,4].
The sequelae of OSAH can be serious. There is a causal link with
hypertension [5]. A recent meta-analysis estimated the risk of
cardiovascular disease (CVD) to be 2.5 times higher in patients with
moderate-severe OSAH [6]. This association is supported by bio-
logically plausible mechanisms. Intermittent hypoxia, micro-
arousals and excessive negative intrathoracic pressure swings may
all play a role, mediated via sympathetic activation, oxidative stress
and inﬂammation, as well as through direct cardiac effects [7].
There is also evidence for improvement in cardiovascular outcomes
when OSA is treated. While the case is strongest for hypertension,
there may be other cardiovascular beneﬁts, although conclusive
evidence is still needed. There are other consequences of OSAH.
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Impaired vigilance is responsible for a two to three fold increase in
road trafﬁc accident (RTA) risk [8], while health related quality of
life (HRQoL) is also diminished [9]. Healthcare usage is almost
doubled in OSAH, with one of the main determinants of increased
cost being CVD [10].
The AHI is an objective, sensitive and speciﬁc measure of the
severity of OSAH. It allows useful if arbitrary disease categorisation,
although differing hypopnoea deﬁnitions introduce variability. The
American Academy of SleepMedicine (AASM) deﬁnesmild OSAH as
an AHI of 5e14 events per hour; moderate OSAH as 15e30 events
per hour; and severe OSAH as an AHI of greater than 30 events per
hour [11].
Impact on excessive daytime sleepiness (EDS) is routinely
measured when evaluating the effectiveness of different treat-
ments for OSAH. The extensively validated Epworth sleepiness
scale (ESS) is the most frequently used instrument [12]. As a sub-
jective measure it is susceptible to signiﬁcant placebo effects [13]
but it has been found to be the best among a range of validated
outcome measures in predicting real response to OSAH treatment
[14].
For milder cases of OSAH, treatment focuses on lifestyle modi-
ﬁcation (weight loss, smoking cessation, reduction of alcohol
intake, position management and sleep hygiene). When the
symptoms of OSAH are more severe deﬁnitive treatment is usually
recommended, most commonly CPAP. Pressure generated by an
electric air pump is applied to the upper airway via a face mask. It
provides a pneumatic splint which maintains pharyngeal patency
during sleep. There is good evidence that CPAP reduces obstructive
events and improves daytime sleepiness, cognitive function, HRQoL
and CVD risk factors. However almost all trials have been
conducted in patients with moderate-severe OSAH [9,15,16], and
CPAP intolerance, which frequently undermines its effectiveness,
may be a particular problem in milder disease [17].
Mandibular advancement devices (MAD) are an alternative to
CPAP in the treatment of OSAH. Worn intraorally during sleep, they
can prevent upper airway collapse by holding the mandible and
tongue forward. A wide variety of devices are available, covering a
range of sophistication and cost. Improvement in respiratory events
has been associated with MAD-mediated increase in upper airway
dimensions [18]. The positive treatment effect, coupled with
compliance rates that may be higher than for CPAP, suggest MADs
are an effective treatment in patients with mild to moderate OSAH.
Three meta-analyses have examined the evidence for the use of
MAD in OSAH [9,15,19]. Lim et al. [19] reviewed 17 RCTs on MAD
involving 831 patients. They concluded that MADs were effective in
reducing AHI, ESS and other measures of sleep-disordered
breathing compared with conservative management (CM), but
less than CPAP. Effects on quality of life, symptoms, CVD risk factors
and RTAs were unclear due to the small number of studies and
inconsistent methodology. An earlier Cochrane review [15]
compared CPAP to controls and MADs in separate analyses. CPAP
was best at reducing AHI. However, ESS improvements were similar
for CPAP and MADs, with both better than no treatment. There was
evidence of greater CPAP effectiveness with increasing baseline AHI
severity. McDaid et al. [9] compared CPAP with control (placebo
and conservative treatment) and MAD in separate analyses. They
identiﬁed 48 studies reporting at least one measure of clinical
effectiveness. Twenty-nine included ESS as the primary outcome.
Most studies included people with severe disease by baseline AHI.
There was less evidence of a difference between CPAP and MAD
impacts on ESS, compared to CPAP and control. The small number
of trials directly comparing these two treatments makes it difﬁcult
to elucidate the reasons for the differing AHI and ESS effects, but
others have also noted only moderate correlation between AHI and
ESS [20]. In commonwith Lim et al., [19] results regarding quality of
life and cardiovascular risks were inconclusive due to the small
numbers of trials and patients, short follow up and heterogeneous
outcome measures.
This meta-analysis was designed to update systematic reviews
of the effects on OSAH of MAD and CPAP, compared with each other
and with CM, and to estimate the effect on AHI and ESS of both
treatments. This includes assessment of heterogeneity due to
baseline AHI severity, baseline ESS severity, trial methodology and
duration of follow up.
Methods
Search strategy for the systematic review
The systematic review included RCTs of adult (16 y or older)
OSAH patients with at least one arm randomised to MAD or CPAP.
Exclusions were: studies comparing two different MAD or two
different types of CPAP (differences within treatment modalities
are small and numerous different devices are available), animal
studies, non-randomised studies and trials published in a language
other than English.
Information sources used to identify studies
The search strategy updated two existing systematic reviews
[9,19] to August 2013, when the main analysis was conducted. The
main stages of the search are described below.
1) All studies reported in the McDaid et al. systematic review [9]
were included, which searched 14 databases up to November
2006 and included all RCTs of CPAP compared with either MAD
or a non-MAD control. This search was repeated in 2012 by the
authors of McDaid et al. (York University Centres for Reviews
and Dissemination and for Health Economics) and results were
shared with the authors of this article. This search strategy was
repeated, by the authors, to retrieve articles fromMarch 2012 to
August 2013 using MEDLINE, Embase and the Science Citation
Index, the three most sensitive databases reported by McDaid
[9], to identify recent trials.
2) The search by McDaid et al. [9] did not include studies of MAD
against CM. Therefore additional papers were identiﬁed from
Lim [19], and an updated version of the Lim strategy re-run to
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cover the period June 2008 and August 2013, using MEDLINE,
Embase and the Science Citation Index.
3) Reference lists of papers were searched and supplemented by
the research team's expert knowledge of the area to identify
other trials missed in updated searches.
Inclusion criteria
All studies published by McDaid et al. and Lim et al. were
reviewed. For subsequent searches, titles and abstracts were
screened independently for relevance by two of the authors (of MB,
MG, AC-J, RC and MP). Disagreements were resolved by consensus.
Patients
Full papers were retrieved for RCTs of adult patients with newly
diagnosed or existing OSAH of any severity and conﬁrmed using an
appropriate method such as polysomnography. Studies were
excluded if OSAH was not the predominant diagnosis, for example
sleep disordered breathing associated with heart disease, stroke or
dementia.
Interventions
Trials with at least one randomised comparison of i) MAD (ﬁxed
or adjustable) against CM ii) CPAP (ﬁxed or autotitrating) against
CM, iii) MAD (ﬁxed or adjustable) against CPAP (ﬁxed or autoti-
trating) were included. CM included usual care, recommendation to
lose weight or reduce alcohol consumption, sham device, placebo
pill or postural device aimed at discouraging supine sleeping.
Although data were extracted from studies where a surgical
intervention was compared with either MAD or CPAP, this was not
considered to be CM and the studies were excluded from the
meta-analysis.
Trial methods
All trial methodologies that included randomised allocation
were included. In practice, trials were either i) crossover in design,
with all patients receiving at least one active treatment and the
order of treatment determined at random, or ii) individually-
randomised, parallel-groups trials, with each patient receiving
one treatment only. Trials in which the treatment duration
was  one week were excluded since this period was considered
inadequate to produce a treatment effect.
Outcome measurements
This review focusses on AHI and ESS, the most commonly
reported outcomes used to assess treatment effectiveness.
Data extracted from published studies
For previously published reviews (see above), estimates of
treatment effects recorded in the relevant papers were used after
checking their accuracy in the published article or abstract [9,19].
For newly identiﬁed studies information from full papers was
extracted independently by two of the authors (of MB, MG, AC-J, RC
and MP) and entered onto a bespoke data extraction form. Queries
were resolved by consensus. Studies available as abstracts only
were included provided that we could verify the inclusion and
exclusion criteria, and at least one of the outcomes of interest was
reported. For the updated review of MAD, if data in the published
abstract, index paper, or a related publication were unclear, the
authors were approached for further information. It was not
possible within the timescale of the study to pursue authors of
trials involving CPAP for data that were not published in the
abstract, index paper, or a related publication.
Data extracted included details of the patient sample and
baseline characteristics, intervention and comparator, outcome
measurements, trial methodology, treatment duration and results.
Mean differences between the groups for continuous outcomes,
and standard errors of the group differences, were extracted for the
meta-analysis.
Quality assessment
The Jadad score was calculated as a measure of quality for
consistency with previously published reviews [9,19]. The Jadad
score was calculated by one reviewer and checked by a second.
Publication bias
Funnel plots were examined as an informal method of assessing
publication bias. These showed little evidence of asymmetry but
the number of studies was too small for more formal analysis.
Data analysis
Three separate meta-analyses were conducted, one for each of
the comparisons i) MAD against CM, ii) MAD against CPAP and iii)
CPAP against CM. Meta-analyses used random effects methods and
were implemented using metan and related commands in STATA
version 12 [21] and in WinBUGS [22]. In brief, this model was
formulated as follows. From each study iwe have an estimate of the
treatment effect compared with the control treatment as bbi and we
assume that these estimates follow a Gaussian distribution with
bbibi  Nbi; s2i 
where bi is the underlying mean treatment effect and s2i is the
standard error in trial i. We assume that the trials are exchangeable
a priori and that the underlying trial parameters bi are drawn from a
Gaussian distributionwith mean m¼ E[bi] and variance t2 ¼ Var[bi].
The methods used in STATA follow DerSimonian and Laird
(1986) [21] who take a classical approach to random-effects meta-
analysis. The expected treatment effect m is estimated as the
weighted average,
bm ¼Xbbi bwi.bwi
where the weights are given by the inverse of the estimated total
variance bwi ¼ 1=ðs2i þ t2Þ.
The standard error of bm is approximated by ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃð1=P bwiÞp and an
approximate 95% conﬁdence interval is given by
bm±1:96 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ1.X bwi
r
:
All outcomes were assumed to be normally distributed. The
standard error term s2i was estimated by the within-trial standard
error. Where only 95% conﬁdence intervals were available the
standard error was estimated using (upper limit-lower limit)/3.92.
Although we investigated combining all trial results in a formal
network meta-analysis, differences in control trial samples meant
that these comparisons were unsound and these results are not
reported. Informal indirect comparisons are discussed.
Heterogeneity between studies was represented by the I2
statistic and the c2 test for heterogeneity [23]. In order to investi-
gate the sources of heterogeneity the combined treatment effects
for AHI and ESS were re-estimated in each of the following
subgroups.
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1) Mean baseline AHI events/hour: mild (AHI 5e14), moderate
(AHI 15e30) and severe (AHI > 30). If only mean DI, rather than
mean AHI was available, severity was classiﬁed as: mild (DI
5e9), moderate (DI 10e30) and severe (DI > 30).
2) Mean baseline ESS score: normal/mild (0e9), moderate (10e15)
and severe (16e24)
3) Study design: parallel and crossover
4) Treatment duration for studies involving MAD: short (2e12 wk)
and long (>12 wk), and for studies of CPAP against CM: short
(2e4 wk) medium (5e12 wk) and long (>12 wk)
Results
Quantity and quality of studies
Results of the literature search are summarised in Fig. 1. After
combining studies identiﬁed in previous reviews which had not
been superceded by subsequent reports (44 studies) with those
identiﬁed in the current review (27 studies) 71 trials were included.
Three studies comparedMAD, CPAP and CM and so each contribute
to three separate comparisons, giving a total of 77 separate com-
parisons [24e26]. Most studies focussed on the effectiveness of
CPAP.
Summary of included studies
Summaries of the baseline characteristics for the included
studies are shown in Table 1. Twelve studies (629 patients)
compared MAD against CM, 13 studies (746 patients) compared
MAD against CPAP and 52 studies (5400 patients) compared CPAP
with CM.
Patient characteristics
As expected the study samples included a large proportion of
men, ranging from 65% to 100%, median 81%. The reported mean
ages ranged from 44.0 to 59.2 y. Most trial samples were over-
weight or obese on average, with mean body mass index ranging
from 28.3 kg/m2 to 35.1 kg/m2.
In general CPAP trials were conducted in patient samples with
more severe AHI/ESS at baseline than were MAD trials. Of 51 CPAP-
CM comparisons that recorded average baseline AHI, 35 (69%) were
in patients with an average AHI greater than 30 events/hour (severe
OSAH) compared with three of 12 (25%) MAD-CM trials. Only ﬁve
CPAP-CM trials were in patients with mild AHI at baseline. Most
MAD-CM trials (seven of 12, 58%) were in patients with moderate
AHI at baseline. In trials directly comparingMADwith CPAP, one did
not record baseline AHI, eight of the remaining 12 (67%) reported
moderate and four (33%) reported severe average baseline AHI.
Average baseline ESS was available for 60 comparisons. Of these,
all nine MAD-CPAP trials and seven of the eight (88%) MAD-CM
trials reported moderate mean baseline ESS. Of the 43 CPAP-CM
comparisons, six (14%) had normal/mild, 32 (74%) had moderate
and ﬁve (12%) had severe mean baseline daytime sleepiness ac-
cording to ESS.
Intervention and comparators
Thirteen (53%) of 25 trials involving MAD used adjustable de-
vices, 10 (40%) used ﬁxed devices and two (8%) did not report the
type. In 13 trials (52%) the MAD was compared directly with CPAP,
nine (36%) used a sham MAD, one compared MAD with a placebo
tablet, one with conservative treatment and onewith no treatment.
Of 65 trials involving CPAP 54 (83%) used ﬁxed CPAP, six (9%)
autotitrating machines and ﬁve (8%) did not report this informa-
tion. Excluding the 13 trials comparing CPAP with MAD, 29 of 52
(56%) compared CPAP with a sham version, seven (13%) with
placebo tablet and nine (13%) with conservative management or no
treatment.
Study design
Trials were almost invariably small (see Table 1). The median
number of patients randomised in MAD-CM trials was 48 (range
21e91), in MAD-CPAP trials 51 (range 20e122) and in CPAP-CM 52
(range 10 to 1105). Duration of treatment was generally short, with
60 of 76 (79%) trials that reported duration having a treatment
period of 12 wk or less. Nine of 13 (69%) MAD-CPAP trials had a
crossover design, comparedwith six of 12 (50%) MAD-CM trials and
16 of 52 (31%) CPAP-CM trials.
Study quality
The Jadad scorewas available for 69 of the 71 trials, with average
score close to three for comparisons against CM. The mean Jadad
score was 2.9 in MAD-CM trials, 2.3 in MAD-CPAP comparisons and
3.1 in CPAP-CM trials, with the lower mean scores in MAD-CPAP
comparisons mainly attributable to the difﬁculty in blinding the
two active treatments.
Apnoea-hypopnoea index
MAD compared with CM
Twelve studies (629 patients) provided an estimate of the effect
on AHI, but one of these [27] only provided a point estimate and
could not be included in the meta-analysis (see Fig. 2). The mean
difference (reduction) in AHI for MAD compared with CM
was9.29 events/hour, (95%CI12.28,6.30), p < 0.001. Therewas
signiﬁcant heterogeneity between studies (I2 ¼ 60%, p ¼ 0.005),
partly arising from differences in baseline severity of AHI. Only two
studies were in patients with mild OSAH and the treatment effect
for these studies differed by more than nine events per hour. Six of
the 11 studies had a crossover design and these studies had more
heterogeneous results than parallel group trials (see Table 2).
Treatment effects were greater in crossover trials than in parallel
group designs, although the difference between designs was not
large. In addition, treatment effects in trials of short duration were
larger than in longer-term studies.
MAD compared with CPAP
From 13 trials (746 patients) the estimated overall difference in
AHI was 7.03 events/hour (95%CI 5.41, 8.66), p < 0.001, with CPAP
having lower post-treatment AHI thanMAD (see Fig. 3). Again there
was important heterogeneity between study results, with smaller
studies [28e31] and shorter studies [28,29,31], estimating greater
effects than larger and longer studies. No MAD-CPAP head-to-head
comparisons were reported in patients with mild baseline AHI (see
Table 3) and all nine trials reported moderate average ESS at
baseline. Estimates of the difference in post-treatment AHI were
consistent and were not related to baseline AHI (moderate
compared with severe), trial design or duration of treatment, with
all signiﬁcantly lower, by approximately seven events per hour,
after CPAP (see Table 3).
CPAP compared with CM
Of 52 CPAP-CM trials, 25 (1596 patients) reported post-
treatment AHI, with combined effect of 25.37 events/hour (95%
CI 30.67, 20.07), p < 0.001 (see Fig. 4). There was a signiﬁcant
amount of heterogeneity between study results, both overall and
within strata. Some heterogeneity could be explained by baseline
AHI severity and the potential for treatment effect is naturally
governed by the extent of disease in the sample. Only one of these
studies was in patients with mild baseline AHI [32] and the esti-
mated mean effect in this trial was small at2.40 events/hour (95%
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CI 3.67, 1.13). The mean difference in AHI between CPAP and CM
patients increased with baseline severity, from 13.67 events/hour
(95%CI 16.13, 11.20) for moderate AHI at baseline to 33.04
events/hour (95%CI 39.75, 26.34) for severe (see Table 4). One
trial reported normal/mild ESS at baseline but, despite this, baseline
AHI was severe and the treatment effect was large. With the
exception of this study the effect of CPAP on AHI was related to
baseline ESS severity. There was some evidence that the treatment
was less effective in crossover trials compared with parallel group
trials. In common with MAD-CM comparisons, trials with longer
treatment duration had lower treatment effects than shorter trials
(see Table 4).
Epworth sleepiness scale
MAD compared with CM
Ten studies reported a point estimate for ESS but only nine
reported the standard error of the treatment effect and so could be
included in the meta-analysis. For these nine studies (485 patients)
the combined treatment effect on ESSwas1.64 (2.46,0.82) (see
Fig. 1. Results of the literature search. Abbreviations: CPAP: continuous positive airway pressure; MAD: mandibular advancement device; TOMADO: trial of oral mandibular
advanacement devices for obstructive sleep apnoea.
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Table 1
Baseline characteristics of patients and study designs for randomised controlled trials.
Study Design Number randomised (analysed) Baseline severity
(AHI or DI)
Baseline symptom
severity (ESS)
Duration of each
treatment (weeks)
MAD compared with CM
Aarab et al. 2011 [26] P 42 Moderate Moderate 26
Andren et al. 2013 [27] P 72 Moderate Moderate 13
Barnes et al. 2004 [24] C 80 Moderate Moderate 12
Blanco et al. 2005 [34] P 24 (15) Severe Severe 13
Duran et al. 2002 [47] C 44 (38) Mild NR NR
Gotsopoulos et al. 2002 [48] C 85 (73) Moderate NR 4
Hans et al. 1997 [33] P 24 Moderate NR NR
Johnston et al. 2002 [49] C 21 (18) Severe Moderate 4e6
Lam et al. 2007 [25] P 67 Moderate Moderate 10
Mehta et al. 2001 [50] C 28 Moderate NR 3
Petri et al. 2008 [51] P 52 Severe Moderate 4
Quinnell et al. 2014 [35] P 90 Mild Moderate 4
MAD compared with CPAP
Aarab et al. 2011 [26] P 43 Moderate Moderate 26
Barnes et al. 2004 [24] C 80 Moderate Moderate 12
Engelman et al. 2002 [46] C 51 (48) Severe Moderate 8
Ferguson et al. 1996 [29] C 27 Moderate NR 17
Ferguson et al. 1997 [28] C 24 (19) Moderate NR 17
Fleetham et al. 1998 [31] P 101 Severe Moderate 12
Hoekema et al. 2008 [52] P 103 Severe Moderate 8
Gagnadoux et al. 2009 [53] C 59 Severe Moderate 8
Lam et al. 2007 [25] P 68 Moderate Moderate 10
Olson et al. 2002 [45] C 24 NR NR 14
Phillips et al. 2013 [36] C 122 Moderate Moderate 4
Randerath et al. 2002 [30] C 20 Moderate NR 6
Tan et al. 2002 [54] C 24 (21) Moderate Moderate 8
CPAP compared with CM
Aarab et al. 2011 [26] P 43 Moderate Moderate 26
Arias et al. 2005 [55] C 27 Severe NR 12
Arias et al. 2006 [56] P 23 Severe NR 12
Ballester et al. 1999 [57] P 105 Severe Moderate 12
Barbe et al. 2001 [58] P 55 Severe Normal/Mild 6
Barbe et al. 2012 [59] P 725 Severe Normal/Mild 156
Barnes et al. 2002 [60] C 42 Mild Moderate 8
Barnes et al. 2004 [24] C 80 Moderate Moderate 12
Becker et al. 2003 [61] P 60 Severe Moderate 9
Campos-Rodriguez et al. 2006 [62] P 72 Severe Moderate 4
Chakravorty et al. 2002 [63] P 71 Severe Severe 12
Coughlin et al. 2007 [64] C 35 Severe Moderate 6
Craig et al. 2012 [65] P 391 Mild Normal/Mild 26
Diafera et al. 2013 [66] P 100 Severe Moderate 13
Drager et al. 2006 [67] P 16 Severe NR 12
Drager et al. 2007 [68] P 24 Severe Moderate 17
Duran-Cantolla et al. 2010 [69] P 340 Severe Moderate 12
Engleman et al. 1996 [70] C 16 Severe NR 3
Engleman et al. 1997 [71] C 18 Mild Moderate 4
Engleman et al. 1998 [72] C 23 Severe Moderate 4
Engleman et al. 1999 [73] C 37 Mild Moderate 4
Faccenda et al. 2001 [74] C 71 Severe Moderate 4
Haensel et al. 2007 [75] P 50 Severe NR 2
Henke et al. 2001 [76] P 45 Severe Severe 2
Hoyos et al. 2012 [77] P 65 Severe Moderate 12
Hui et al. 2006 [78] P 56 Severe Moderate 12
Jenkinson et al. 1999 [79] P 107 Moderate Severe 4
Kaneko et al. 2003 [80] P 21 Severe Normal/Mild 4
Kushida et al. 2012 [81] P 1105 Severe Moderate 26
Lam et al. 2007 [25] P 67 Moderate Moderate 10
Lee et al. 2012 [82] P 71 Severe Moderate 3
Lozano et al. 2010 [83] P 75 Severe Normal/Mild 13
Mansﬁeld et al. 2004 [84] P 55 Moderate Moderate 12
Marshall et al. 2005 [85] C 31 Moderate Moderate 3
Monasterio et al. 2001 [86] P 142 Moderate Moderate 24
Montserrat et al. 2001 [87] P 46 Severe Severe 6
Norman et al. 2006 [88] P 33 Severe Moderate 2
Pepperell et al. 2002 [16] P 118 Severe Severe 4
Phillips et al. 2011 [89] C 20 Severe Moderate 8
Redline et al. 1998 [90] P 111 Moderate Moderate 8
Robinson et al. 2006 [91] C 35 Moderate Normal/Mild 4
Sharma et al. 2011 [92] C 90 Severe Moderate 13
Siccoli et al. 2008 [14] P 102 Severe Moderate 4
Simpson et al. 2012 [93] P 36 Severe NR 12
Skinner et al. 2004 [94] C 10 Moderate Moderate 4
Skinner et al. 2008 [95] C 20 Moderate Moderate 4
(continued on next page)
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Fig. 5 and Table 5). There was signiﬁcant heterogeneity, with small
studies [33,34]more likely to report large treatment differences (see
Fig. 5). One study was conducted in patients with mild AHI at
baseline and the effect on ESS in this study was between, and of a
similar order to, estimates from trials in patient populations with
moderate and severe baseline AHI [35]. Due to the small number of
trials and the large inﬂuence of the Blanco et al. [34] study itwas not
possible to reliably assess reasons for heterogeneity.
MAD compared with CPAP
Of the 12 studies directly comparing MAD and CPAP 10 trials (675
patients) recorded ESS with a combined effect of 0.67 (95%CI 0.11,
1.44), p ¼ 0.093 (see Fig. 6). The positive estimate indicates that the
post-treatment ESS was lower (better) in the CPAP group. There was
less between-study heterogeneity in this analysis and results of
stratiﬁed analysis show that any treatment effect was small, with
clinically signiﬁcant differences only likely for those with severe
baselineAHI (see Table 6).However thenumberand size of trialsmade
reliable conclusions impossible, particularly regarding mild OSAH.
CPAP compared with CM
Thirty-eight of the 52 CPAP-CM trials (4894 patients) reported
the estimated post-treatment effect on ESS. These trials were
plotted in Fig. 7 with combined treatment effect of 2.23 (95%
Table 1 (continued )
Study Design Number randomised (analysed) Baseline severity
(AHI or DI)
Baseline symptom
severity (ESS)
Duration of each
treatment (weeks)
Spicuzza et al. 2006 [96] P 25 Severe NR 4
Tomfohr et al. 2011 [97] P 71 Severe Moderate 3
Von Kanel et al. 2006 [98] P 28 Severe NR 2
Weaver et al. 2012 [32] P 281 Mild Moderate 8
Weinstock et al. 2012 [99] C 50 Severe NR 8
West et al. 2007 [100] P 42 NR Moderate 12
Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5e14, DI 5e9), moderate (AHI 15e30, DI 10e30) and severe (AHI > 30, DI > 30).
Mean baseline ESS 0e9 (normal/mild) 10e15 (moderate) 16e24 (severe).
Abbreviations: apnoea-hypopnoea index (AHI); CPAP: continuous positive airway pressure; C: Crossover; DI: desaturation index; ESS: Epworth Sleepiness Score; MAD:
mandibular advancement device; NR: not recorded or unclear; P: parallel.
Fig. 2. Meta-analysis of AHI results from trials of MAD compared with conservative management, stratiﬁed by baseline AHI. Mean baseline AHI/DI (events/hour); mild (AHI 5e14, DI
5e9) moderate (AHI 15e30 DI 10e30) severe (AHI > 30 DI > 30). Abbreviations: AHI: apnoea-hypopnoea index; CI: conﬁdence interval; continuous positive airway pressure (CPAP);
DI: desaturation index; ES: effect size; ID: identiﬁcation; MAD: mandibular advancement device.
L.D. Sharples et al. / Sleep Medicine Reviews 27 (2016) 108e124114
Table 2
Subgroup analysis of AHI results (events per hour) for comparisons of MAD against conservative management (negative estimates favour MAD).
Subgroup Number of studies Difference in AHI:
MAD-control (95%CI)
P value for effect I2 Heterogeneity P value
Baseline AHI
Mild [35,47] 2 7.79 (16.38, 0.79) 0.075 65% 0.091
Moderate [24e26,33,48,50] 6 10.72 (14.59, 6.85) <0.001 52% 0.064
Severe [24,49,51] 3 7.95 (15.94, 0.05) 0.051 32% 0.232
Baseline ESS
Moderate [24e26,35,49,51] 6 6.69 (8.98, 4.41) <0.001 35% 0.177
Severe [34] 1 2.10 (12.33, 8.13) 0.687 e e
Trial design
Crossover [24,35,47e50] 6 10.17 (14.27, 6.07) <0.001 76% 0.001
Parallel [25,26,33,34,51] 5 8.57 (12.39, 4.75) <0.001 0% 0.533
Duration of treatment
2e12 wk [24,25,33,35,48e51] 8 9.69 (13.27, 6.12) <0.001 68% 0.003
>12 wk [26,34] 2 6.78 (13.24, 0.33) 0.039 23% 0.56
Overall MAD compared with control
Overall 11 9.29 (12.28, 6.30) <0.001 60% 0.005
Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5e14, DI 5e9), moderate (AHI 15e30, DI 10e30) and severe (AHI > 30, DI > 30).
Mean baseline ESS score: normal/mild (0e9), moderate (10e15) and severe (16e24).
Abbreviations: AHI: apnoea-hypopnoea index; CI: conﬁdence interval; DI: desaturation index; I2: proportion of total variability explained by heterogeneity; MAD: mandibular
advancement device.
Fig. 3. Meta-analysis of AHI results from trials of MAD compared with CPAP. Mean baseline AHI/DI (events/hour): mild (AHI 5e14, DI 5e9), moderate (AHI 15e30 DI 10e30) and
severe (AHI > 30 DI > 30). Abbreviations: AHI: apnoea-hypopnoea index; CI: conﬁdence interval; CPAP: continuous positive airway pressure; DI: desaturation index; ES: effect size;
ID: Identiﬁcation; MAD: mandibular advancement device; NR: baseline AHI not recorded.
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Table 3
Subgroup analysis of AHI results (events per hour) for comparison of MAD against CPAP (positive estimates favour CPAP).
Subgroup Number of studies Difference in AHI: MAD-CPAP (95%CI) P value for effect I2 Heterogeneity P value
Baseline AHI (1 study did not record baseline AHI)
Moderate [24e26,28e30,36,54] 8 7.48 (5.77, 9.19) <0.001 28% 0.203
Severe [31,46,52,53] 4 7.22 (3.20, 11.25) <0.001 74% 0.010
Baseline ESS
Moderate [24e26,31,36,46,52e54] 9 6.70 (4.86, 8.54) <0.001 57% 0.098
Trial design
Crossover [24,28e30,36,45,46,53,54] 9 6.91 (5.11, 8.71) <0.001 48% 0.054
Parallel [25,26,31,52] 4 7.72 (3.58, 11.87) <0.001 69% 0.022
Duration of treatment
2e12 wk [24,25,30,31,36,46,52e54] 9 7.19 (5.25, 9.12) <0.001 59% 0.013
>12 wk [26,28,29,45] 4 6.78 (3.25, 10.31) <0.001 42% 0.157
Overall MAD compared with CPAP
Overall 13 7.03 (5.41, 8.66) <0.001 52% 0.015
Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5e14, DI 5e9), moderate (AHI 15e30, DI 10e30) and severe (AHI > 30, DI > 30).
Mean baseline ESS score: normal/mild (0e9), moderate (10e15) and severe (16e24).
Abbreviations: AHI: apnoea-hypopnoea index; CI: conﬁdence interval; CPAP: continuous positive airway pressure; DI: desaturation index; I2: proportion of total variability
explained by heterogeneity; MAD: mandibular advancement device.
Fig. 4. Meta-analysis of AHI results from trials of CPAP compared with conservative management, stratiﬁed by baseline AHI. Mean baseline AHI/DI (events/hour): mild (AHI 5e14, DI
5e9), moderate (AHI 15e30 DI 10e30) and severe (AHI > 30 DI > 30). Abbreviations: AHI: apnoea-hypopnoea index; CI: conﬁdence interval; CPAP: continuous positive airway
pressure; DI: desaturation index; ES: effect size; ID: identiﬁcation.
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Table 4
Subgroup analysis of AHI results (events/hour) for comparison of CPAP against conservative management (negative estimates favour CPAP).
Subgroup Number of studies Difference in AHI: CPAP-control
(95%CI)
P value for effect I2 Heterogeneity
P value
Baseline AHI
Mild [32] 1 2.40 (3.67, 1.13) <0.001 e e
Moderate [24e26,84,86,94,95] 7 13.67 (16.13, 11.20) <0.001 47% 0.081
Severe [16,61,63,66,67,75e77,80,82,88,89,93,96e99] 17 33.04 (39.75, 26.34) <0.001 90% <0.001
Baseline ESS
Normal/Mild [80] 1 32.50 (43.55, 21.45) <0.001 e e
Moderate [24e26,32,61,66,77,82,84,86,88,89,94,95,97] 15 17.54 (22.51, 12.56) <0.001 95% <0.001
Severe [16,63,76] 3 34.73 (58.90, 10.57) 0.005 95% <0.001
Trial design
Crossover [24,89,94,95,99] 5 19.71 (27.95, 11.48) <0.001 87% <0.001
Parallel [16,25,26,32,61,63,66,67,75e77,80,82,84,86,88,93,96e98] 20 27.08 (33.68, 20.48) <0.001 97% <0.001
Duration of treatment
2e4 wk [16,75,76,80,82,88,94e98] 11 32.90 (43.78, 22.02) <0.001 93% <0.001
5e12 wk [24,25,32,61,63,67,77,84,89,93,99] 11 22.34 (29.84, 14.85) <0.001 96% <0.001
>12 wk [26,66,86] 3 14.25 (19.03, 9.46) <0.001 82% 0.004
Overall CPAP compared with controls
Overall 25 25.37 (30.67, 20.07) <0.001 96% <0.001
Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5e14, DI 5e9), moderate (AHI 15e30, DI 10e30) and severe (AHI > 30, DI > 30).
Mean baseline ESS score: normal/mild (0e9), moderate (10e15) and severe (16e24).
Abbreviations: AHI: apnoea-hypopnoea index; CI: conﬁdence interval; CPAP: continuous positive airway pressure; DI: desaturation index; I2 proportion of total variability
explained by heterogeneity.
Fig. 5. Meta-analysis of ESS results from trials of MAD compared with conservative management, stratiﬁed by baseline AHI. Mean baseline Apnoea-Hypopnoea Index/Desaturation
Index (AHI/DI) events/hour: mild (AHI 5e14, DI 5e9) moderate (AHI 15e30 DI 10e30) severe (AHI > 30 DI > 30). Abbreviations: AHI: apnoea-hypopnoea index; CI: conﬁdence
interval; DI: desaturation index; ES: effect size; ESS: Epworth Sleepiness Scale; ID: identiﬁcation; MAD: mandibular advancement device.
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CI 2.76, 1.71), p < 0.001. Again there was signiﬁcant heteroge-
neity, and some stratiﬁed analyses were reported in Table 7. In
commonwith AHI the effect of CPAP on ESS increased with baseline
AHI severity, from 1.23 (95%CI 2.19, 0.27) for the mild group
to 2.64 (95%CI 3.44, 1.84) for the severe group. One study did
not report baseline AHI. Trial design had less impact on outcomes
but longer duration of treatment was associated with decreasing
treatment effect, which again mirrors the analysis of AHI.
Discussion
Our study was based on a systematic review of the available
literature and robust, prospective design. The updated meta-
analyses offer stronger insights into the relative effectiveness of
MAD and CPAP in patients with mild-moderate OSAH. In addition
the effects of baseline severity have been highlighted and used to
explain some of the differences in effects between MAD and CPAP.
Table 5
Subgroup analysis of ESS results for comparison of MAD against conservative management (negative estimates favour MAD).
Subgroup Number of studies Difference in ESS: MAD-controls (95%CI) P value for effect I2 Heterogeneity P value
Baseline AHI
Mild [35] 1 2.01 (2.70, 1.32) <0.001 42% 0.142
Moderate [24e26,33,48] 5 1.38 (2.48, 0.27) 0.15 73% 0.025
Severe [34,49,51] 3 2.68 (5.89, 0.54) 0.103 48% 0.051
Baseline ESS
Moderate [24e26,35,49,51] 6 1.36 (2.07, 0.64) <0.001 e e
Severe [34] 1 8.50 (13.64, 3.36) 0.001 55% 0.037
Trial design
Crossover [24,35,48,49] 4 1.75 (2.25, 1.25) <0.001 2% 0.380
Parallel [25,26,33,34,51] 5 2.18 (4.80, 0.44) 0.102 68% 0.015
Duration of treatment
2e12 wk [24,25,33,35,48,49,51] 7 1.75 (2.22, 1.28) <0.001 0% 0.521
>12 wk [26,34] 2 3.26 (13.15, 6.63) 0.518 90% 0.001
Overall MAD compared with controls
Overall 9 1.64 (2.46, 0.82) <0.001 48% 0.051
Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5e14, DI 5e9), moderate (AHI 15e30, DI 10e30) and severe (AHI > 30, DI > 30).
Mean baseline ESS score: normal/mild (0e9), moderate (10e15) and severe (16e24).
Abbreviations: AHI: apnoea-hypopnoea index; CI: conﬁdence interval; DI: desaturation index; ESS: Epworth Sleepiness Scale; I2 proportion of total variability explained by
heterogeneity; MAD: mandibular advancement device.
Fig. 6. Meta-analysis of ESS results from trials of MAD compared with CPAP, stratiﬁed by baseline AHI. Mean baseline AHI/DI (events/hour): mild (AHI 5e14, DI 5e9), moderate (AHI
15e30 DI 10e30) and severe (AHI > 30 DI > 30). Abbreviations: AHI: apnoea-hypopnoea index; CI: conﬁdence interval; CPAP: continuous positive airway pressure; DI: desaturation
index; ES: effect size; ESS: Epworth Sleepiness Scale; ID: identiﬁcation; MAD: mandibular advancement device.
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Table 6
Subgroup analysis of ESS results for comparison of MAD against CPAP (positive estimates favour CPAP).
Subgroup Number of studies Difference in ESS: MAD-CPAP (95%CI) P value for effect I2 Heterogeneity P value
Baseline AHI
Moderate [24e26,28,36,54] 6 0.06 (0.61, 0.72) 0.864 0% 0.659
Severe [31,46,52,53] 4 1.42 (0.24, 3.08) 0.094 68% 0.024
Baseline ESS
Moderate [24e26,31,36,46,52e54] 9 0.81 (0.04, 1.65) 0.062 49% 0.049
Trial design
Crossover [24,28,36,46,53,54] 6 0.54 (0.48, 1.57) 0.301 60% 0.030
Parallel [25,26,31,52] 4 0.97 (0.16, 2.11) 0.093 0% 0.399
Duration of treatment
2e12 wk [24,25,31,36,46,52e54] 8 0.82 (0.09, 1.73) 0.078 55% 0.031
>12 wk [26,28] 2 0.06 (1.66, 1.54) 0.944 0% 0.461
Overall MAD compared with CPAP
Overall 10 0.67 (0.11, 1.44) 0.093 45% 0.059
Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5e14, DI 5e9), moderate (AHI 15e30, DI 10e30) and severe (AHI > 30, DI > 30).
Mean baseline ESS score: normal/mild (0e9), moderate (10e15) and severe (16e24).
Abbreviations: AHI: apnoea-hypopnoea index; CI: conﬁdence interval; CPAP: continuous positive airway pressure; DI: desaturation index; ESS: Epworth sleepiness scale; I2:
proportion of total variability explained by heterogeneity; MAD: mandibular advancement device.
Fig. 7. Meta-analysis of ESS results from trials of CPAP compared with conservative management. Mean baseline AHI/DI (events/hour): mild (AHI 5e14, DI 5e9), moderate (AHI
15e30 DI 10e30) and severe (AHI > 30 DI > 30). Abbreviations: apnoea-hypopnoea index (AHI); conﬁdence interval (CI); continuous positive airway pressure (CPAP); desaturation
index (DI); effect size (ES); Epworth sleepiness scale (ESS); identiﬁcation (ID); baseline AHI not recorded (NR).
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The three pairwise meta-analyses have shown that MAD
results in a signiﬁcant improvement in post-treatment AHI, and
that the estimate of effect was similar irrespective of baseline
AHI. CPAP produces an improvement of approximately three
times that of the combined estimate for MAD. However, the
majority of trials involving CPAP focus on patients with severe
baseline AHI and there was strong evidence that the treatment
effect, compared with CM, was related to baseline AHI severity,
which is natural since a higher baseline allows greater scope for
an absolute decrease. In trials directly comparing MAD with CPAP
the combined estimates favour CPAP but the absolute difference
between them was of the order of seven events per hour, much
less than suggested by indirectly comparing MAD-CM and
CPAP-CM trials. In the few trials of patients with mild baseline
AHI, compared with CM the estimated reduction in AHI due to
CPAP was 2.4 events/hour (95%CI 1.13, 3.67) and due to MAD
was 7.79 events/hour (95%CI 16.38, 0.79). Moreover, there
were no MAD-CPAP trials conducted in patients with mild
average baseline AHI. This evidence suggests that CPAP results in
greater overall effect on post-treatment AHI but the improve-
ment over MAD will be lower in mild disease.
The effect of MAD on subjective daytime sleepiness measured
using the ESS followed a similar pattern but this instrument was
less sensitive to differences than AHI, so that differences in treat-
ment effects between MAD and CPAP were smaller and not sig-
niﬁcant in direct comparisons. From trials of CPAP against CM the
estimated effects were related to baseline EDS severity with
treatment effects (95%CI) on ESS of0.83 (1.16,0.51) for normal/
mild, 2.19 (2.84, 1.53) for moderate and 4.99 (6.51, 3.47) for
severe baseline ESS. This relationship between baseline severity
and effect on ESS was also observed when severity was classiﬁed by
average baseline AHI. When trials of similar baseline characteristics
were compared there was little difference between the effects of
MAD and CPAP on post-treatment ESS when assessed against CM,
and this was reinforced by the results from head-to-head trials. In
the few trials conducted in patients with mild baseline AHI,
compared with CM the estimated reduction in ESS due to CPAP
was 1.23 (95%CI 2.19, 0.27) and due to MAD was 2.01 (95%
CI 2.70, 1.32).
There was some evidence that treatment effects were stronger
in trials of short duration of treatment, which may have a
number of causes. CPAP is intrusive, requiring patients to wear a
face mask during sleep, and there is evidence for a tailing-off of
compliance over time [17]. Although there is some evidence that
MAD may be better tolerated than CPAP in the short term
[36e38], the limited longer-term data available suggest that
compliance with this less intrusive intervention also diminishes
with time [39,40]. For both active treatments progression of the
underlying OSAH may mean that treatment effects decreased
over time. Possible candidate mechanisms would be ageing and
weight gain. Age effects would not be expected to manifest over
the relatively short periods that trials run [41,42]. The evidence
for CPAP use being associated with weight gain remains unclear
but even when demonstrated the degree of increase seems too
small to impact signiﬁcantly on treated OSAH [43]. In any case,
the range of trial durations in this meta-analysis was narrow, and
there were too few trials (and patients) to examine this obser-
vation in detail. Further trials and, more importantly, availability
of individual patient data from all trials, would allow indepth
examination of the characteristics of patients that determine
outcomes.
In almost all comparisons there was signiﬁcant heterogeneity
between trials. Although some of this could be explained by disease
severity, design and treatment duration, unexplained heterogene-
ity remains. Although we used random-effects meta-analysis to
provide unbiased point estimates and robust estimates of precision,
further elucidation of the sources of heterogeneity would be useful.
Routine release of anonymised, individual patient data after trials
have been reported would allow greater exploration of the varia-
tion in treatment outcomes. We strongly support initiatives such as
the Farr Institute in making such data freely available.
Limitations
In the meta-analysis we considered all MAD as a single treat-
ment modality. There were too few studies to allow robust sub-
group analyses and so we were unable to identify the more modest
differences in effects between different MAD. It has been suggested
Table 7
Subgroup analysis of ESS results for comparison of CPAP against conservative management (negative estimates favour CPAP).
Subgroup Number of
studies
Difference in ESS: CPAP-control
(95%CI)
P value for
effect
I2 Heterogeneity
P value
Baseline AHI
Mild [32,60,65,71,73] 5 1.23 (2.19, 0.27) 0.012 59% 0.045
Moderate [24e26,79,84e86,90,91,95] 10 1.82 (2.73, 0.92) <0.001 60% 0.008
Severe [14,16,32,57e65,68,69,71e74,76e78,81,83,87,89,92,97] 22 2.64 (3.44, 1.84) <0.001 86% <0.001
Baseline ESS
Normal/Mild [58,59,65,83,91] 5 0.83 (1.16, 0.51) <0.001 30% 0.222
Moderate [14,24e26,32,57,60e62,64,68,69,71e74,77,78,81,84
e86,89,90,92,95,97,100]
28 2.19 (2.84, 1.53) <0.001 76% <0.001
Severe [16,63,76,79,87] 5 4.99 (6.51, 3.47) <0.001 46% 0.115
Trial design
Crossover [24,60,64,71e74,85,89,91,92,95]; 12 2.32 (3.33, 1.31) <0.001 79% <0.001
Parallel [14,16,25,26,32,57e59,61e63,65,68,69,76
e79,81,83,84,86,87,90,97,100]
26 2.15 (2.74, 1.55) <0.001 82% <0.001
Duration of treatment
2e4 wk [14,16,62,71e74,76,79,85,91,95,97] 13 2.58 (3.66, 1.51) <0.001 75% <0.001
5e12 wk [24,25,32,57,58,60,61,63,64,69,77,78,84,87,89,90,100] 17 2.20 (3.02, 1.39) <0.001 68% <0.001
>12 wk [26,59,65,68,81,83,86,92] 8 1.87 (2.83, 0.90) <0.001 93% <0.001
Overall CPAP compared with controls
Overall 38 2.23 (2.76, 1.71) <0.001 83% <0.001
Mean baseline AHI (or DI if AHI not reported) events/hour: mild (AHI 5e14, DI 5e9), moderate (AHI 15e30, DI 10e30) and severe (AHI > 30, DI > 30).
Mean baseline ESS score: normal/mild (0e9), moderate (10e15) and severe (16e24).
Abbreviations: AHI: apnoea-hypopnoea index; CI: conﬁdence interval; CPAP: continuous positive airway pressure; DI: desaturation index; ESS: Epworth sleepiness scale; I2:
proportion of total variability explained by heterogeneity; MAD: mandibular advancement device.
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that future meta-analyses distinguish between trials of
non-adjustable MAD and those using adjustable MAD (aMAD) [44].
From the 2006 Cochrane analysis that included only trials
comparing CPAP with aMAD, the ESS effect size was in favour of
MAD, but not signiﬁcantly [15]. We considered performing a similar
subgroup analysis when updating the meta-analysis. However,
device adjustability could not always be determined [31,45]. In any
case, to subdivide along these lines may be too simplistic. For
example, one trial with relatively weak treatment effects has pre-
viously been excluded from aMAD reviews, as they used two non-
adjustable MAD [46]. However they performed ‘pseudotitration’ by
adapting devices to optimise comfort and beneﬁts, and reported
near maximal (80%) jaw protrusion. Meanwhile the potential
advantage of titratable aMAD has sometimes been negated by the
use of uniform protrusion for all patients [30].
Three separate meta-analyses were conducted comparing MAD
against CM, MAD against CPAP and CPAP against CM. A more so-
phisticated analysis would combine the studies into a formal
network meta-analysis, thereby adding strength to all comparisons
and better aligning the studies. Whilst this method was investi-
gated, such analyses rely on the assumption of common control
populations (the associative law), which was unlikely to be true in
this case, given the greater severity of OSAH in samples undergoing
trials of CPAP. Furthermore the heterogeneity observed between
studies suggested that combining results within and across
different treatments may not be sensible. The likely implication of
doing separate meta-analyses would be a loss of precision.
CM encompassed a wide range of control treatments so that
their inﬂuence on the trial-based treatment effects was difﬁcult to
estimate with any precision.
In our systematic review we used the Jadad score as a measure
of study quality which is rather an insensitive tool. It did, however,
provide a broad structure for summarising design features reported
in existing clinical trials.
We restricted this analysis to the two most frequently used
outcome measures in RCTs of OSA treatment and in clinical prac-
tice. Other important clinical outcomes, such as hypertension, were
not always available in published studies, and when they were the
speciﬁc measurement reported was not consistent. In addition, a
wide range of quality of life instruments have been used and robust
meta-analysis of these outcomes has not been possible.
Where there was uncertainty regarding published evidence we
were able to contact authors of trials of MAD but, due to the much
larger number of studies, this was not possible for CPAP trials.
However this mainly applied to trials that were only published in
abstract form and is not likely to have introduced important bias.
Conclusions
For patients with moderate to severe OSAH treatment with
CPAP was the most clinically-effective approach to reduction in
the AHI. For individual patients who are intolerant of CPAP,
treatment with a MAD may also be effective in reducing the AHI
compared with no treatment. Both treatments were effective in
reducing ESS, with CPAP having only a small, additional effect over
MADs. In the few trials of patients with mild OSAH, CPAP and MAD
were similarly effective treatment options and there was little to
choose between them in terms of clinical-effectiveness. There was
signiﬁcant heterogeneity between patients in response to treat-
ment, some of which could be explained by severity of OSAH at
baseline (differences in the effect sizes for CPAP and MAD
increased with baseline severity) and duration of treatment.
Furthermore, there is unavoidable overlap between the arbitrarily
deﬁned severity groups, which introduces ambiguity. However,
reliable stratiﬁcation of patients for management will only be
possible if anonymised individual patient data from these studies
can be made available.
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Practice points
This meta-analysis shows that:
1. CPAP is the most clinically effective treatment at
reducing AHI in moderate to severe OSAH.
2. Both CPAP and MAD reduce subjective sleepiness to a
similar extent in OSAHS.
3. MAD are better than no treatment for CPAP-intolerant
patients and, based on indirect comparisons, may be as
effective as CPAP in mild disease.
Research agenda
Future research needs to address:
1. whether adjustable MAD offer additional benefits in
terms of treatment outcomes over non-titratable devices,
using prospective head-to-head trials.
2. using evidence obtained from (1) the comparative
effectiveness of optimal MAD therapy and CPAP in mild
OSAHS.
3. the need for reliable stratification of patients for man-
agement using data from existing studies.
4. the need to continue to explore the effectiveness and
costs of clinical strategies to predict individual patients'
responses to MAD, to refine treatment choice and effec-
tiveness in OSAHS.
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